Ethynylestradiol内服による前立腺癌症例のgonadotropin抑制効果及び臨床効果に関する検討

Abstract

Serum LH and FSH were measured by radioimmunoassay in five patients with prostatic cancer following castration and oral ethynylestradiol administration. Serum acid phosphatase levels of 10 patients were also examined to evaluate the clinical efficacy of ethynylestradiol for treating the prostatic cancer. Of four castrated patients who received the ethynylestradiol at the dose of 0.15 mg/day for 10-14 days, LH and FSH levels of two patients were suppressed significantly, but were not suppressed to the level of prepubertal value. LH and FSH of two other patients were not suppressed at the dose of 0.15 mg/day. To suppress the gonadotropin of castrated male completely to the prepubertal level, it was needed to administer the ethynylestradiol at the dose of 1.5 mg/day for about 20 days. Of 9 patients who showed the elevated acid phosphatase level before treatment, one patient showed normal level after castration, the acid phosphatase levels of five other patients became normal following the castration and ethynylestradiol administration. From the finding of normal acid phosphatase level following ethynylestradiol administration, ethynylestradiol was considered to be the effective drug for the prostatic cancer.